Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.80 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.80 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.80 |
| ▸ | EGFR | P00533 | 3/20 | 0.80 |
| ▸ | KIT | P10721 | 2/20 | 0.80 |
| ▸ | NEK2 | P51955 | 2/20 | 0.80 |
| ▸ | MELK | Q14680 | 2/20 | 0.80 |
| ▸ | PRKAA1 | Q13131 | 13/20 | 0.77 |
| ▸ | PRKAA2 | P54646 | 12/20 | 0.77 |
| ▸ | FLT3 | P36888 | 3/20 | 0.77 |
| ▸ | GRK5 | P34947 | 3/20 | 0.77 |
| ▸ | PLK4 | O00444 | 2/20 | 0.77 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.77 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.77 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.77 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.77 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.77 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.77 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.77 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16111834 | 1.00 | KDR (0.80) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL16466924 | 0.92 | KDR (0.80) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL19726319 | 0.92 | KDR (0.80) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL16466926 | 0.92 | KDR (0.80) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL12336826 | 0.90 | KDR (0.77) | KDRPDGFRBFGFR1EGFRKIT | |
| Su-11652 SCHEMBL2114096 | 0.89 | KDR (1.00) | KDRPDGFRBFGFR1EGFRKIT | |
| Su-11652 SCHEMBL21067494 | 0.89 | KDR (1.00) | KDRPDGFRBFGFR1EGFRKIT | |
| Su-11652 SCHEMBL29366350 | 0.89 | KDR (1.00) | KDRPDGFRBFGFR1EGFRKIT | |
| Su-11652 SCHEMBL2212420 | 0.89 | KDR (1.00) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL15202704 | 0.89 | KDR (0.84) | KDRPDGFRBFGFR1EGFRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241569-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL INC (US) | 2019-08-08 | — | — | US | disclosed |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2970206-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | Boston Biomedical, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014160401-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014160401-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241569-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | MAP3K2, MAP3K1, MAP3K3 | KDR 484/4885PDGFRB 572/4885FGFR1 505/4885 |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | MAP3K19, MAP3K2, MAP3K3 | KDR 327/4885PDGFRB 495/4885FGFR1 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.